Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26020460 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Amira F Mahdi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biotherapeutics Research Group, Life Sciences Institute, School of Biotechnology, Dublin City University, Dublin 9, D09 NR58 Dublin, Ireland. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Receptors, Estrogen, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Foundation Ireland, Irish Research Council, The Caroline Foundation and the Cancer Clinical Research Trust.
Abstract (Originalsprache)
HER2-positive/oestrogen receptor-positive (HER2+/ER+) represents a unique breast cancer subtype. The use of individual HER2- or ER-targeting agents can lead to the acquisition of therapeutic resistance due to compensatory receptor crosstalk. New drug combinations targeting HER2 and ER could improve outcomes for patients with HER2+/ER+ breast cancer. In this study, the pre-clinical rationale is explored for combining amcenestrant (Amc), a selective oestrogen receptor degrader (SERD), with HER2-targeted therapies including trastuzumab, trastuzumab-emtansine (T-DM1) and tyrosine kinase inhibitors (TKIs). The combination of Amc and anti-HER2 therapies was investigated in a panel of four HER2+/ER+ cell lines: BT-474, MDA-MB-361, EFM-192a and a trastuzumab-resistant variant BT-474-T. Proliferation (IC50 and matrix combination assays) was determined using acid phosphatase assays. HER2/ER and intracellular signalling pathway protein levels/activity were investigated by western blot. Apoptosis was assessed using caspase 3/7 assays. Additivity and synergy were observed between Amc and the TKIs neratinib, lapatinib and tucatinib in all cell lines. Amc increased the anti-proliferative effect of trastuzumab in MDA-MB-361 and BT-474-T. Addition of Amc also increased anti-proliferative efficacy of T-DM1 in BT-474-T. TKI/Amc combinations reduced p-HER2 and ER levels and resulted in increased apoptosis. Higher ER expression in MDA-MB-361 and BT-474-T was associated with greater potential for synergy. In conclusion, the combination of Amc- and HER2-targeted treatments has potential as a therapeutic strategy for the treatment of HER2+/ER+ breast cancer and warrants further clinical investigation to validate safety and efficacy in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biotherapeutics Research Group, Life Sciences Institute, School of Biotechnology, Dublin City University, Dublin 9, D09 NR58 Dublin, Ireland.
- Limerick Digital Cancer Research Centre, Health Research Institute, School of Medicine, University of Limerick, V94 T9PX Limerick, Ireland.
- Department of Medical Oncology, St. Vincent's University Hospital, Dublin 4, D04 T6F4 Dublin, Ireland.
ORCID-Profile: Amira F Mahdi, Denis M Collins
Förderung
- Science Foundation Ireland
- Irish Research Council
- The Caroline Foundation and the Cancer Clinical Research Trust
- The Caroline Foundation
Zitieren
APA
Mahdi, A. F., Ashfield, N., Crown, J., & Collins, D. M. (2025). Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26020460
Vancouver
Mahdi AF, Ashfield N, Crown J, Collins DM. Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26020460
BibTeX
@article{Mahdi2025,
author = {Mahdi, Amira F and Ashfield, Niall and Crown, John and Collins, Denis M},
title = {Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26020460}
}
EUVIMED